Shruthi Karnam

Dr. Shruthi Karnam


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RMRupalatha Maddala
Rupalatha Maddala
LHLeona T. Y. Ho
Leona T. Y. Ho
SKShruthi Karnam
Shruthi Karnam
INIris Navarro
Iris Navarro
AOAnja Osterwald
Anja Osterwald
PRPonugoti Vasantha Rao
Ponugoti Vasantha Rao
Dysregulated levels of growth/differentiation factor-15 (GDF15), a divergent member of the transforming growth factor-beta super family, have been found to be associated with the pathology of various diseases. In this study, we evaluated the levels of GDF15 in aqueous humor (AH) and serum samples derived from primary open-angle glaucoma (POAG) and age- and gender-matched non-glaucoma (cataract) patients to assess the plausible association between GDF15 and POAG. GDF15 levels were determined using an enzyme-linked immunosorbent assay, and data analysis was performed using the Wilcoxon rank sum test, or the Kruskal–Wallis test and linear regression. GDF15 levels in the AH (n = 105) of POAG patients were significantly elevated (by 7.4-fold) compared to cataract patients (n = 117). Serum samples obtained from a subgroup of POAG patients (n = 41) also showed a significant increase in GDF15 levels (by 50%) compared to cataract patients. GDF15 levels were elevated in male, female, African American, and Caucasian POAG patients. This study reveals a significant and marked elevation of GDF15 levels in the AH of POAG patients compared to non-glaucoma cataract control patients. Although serum GDF15 levels were also elevated in POAG patients, the magnitude of difference was much smaller relative to that found in the AH.

18 March 2026 in Progress in Retinal and Eye Research
Verified
Journal Article
Open access
EWEmily Lauren Ward
Emily Lauren Ward
SKShruthi Karnam
Shruthi Karnam
ACAmogh Changavi
Amogh Changavi
MKMatangi Kumar
Matangi Kumar
SMShubham Maurya
Shubham Maurya
JFJohn G. Flanagan
John G. Flanagan
Prostaglandin D2 (PGD2), PGE2, and other prostanoids play important roles in retinal and optic nerve (ON) health and disease, including neovascularization, neuroinflammation, and neurodegeneration. We reviewed the synthesis, expression, regulation, mechanisms, and functions of the principal prostanoids (PGF2α, PGI2, TXA2, PGE2, and PGD2) in the eye. Prostanoids can be difficult to study in-vivo or ex-vivo because they are small, unstable molecules. To address this, we incorporated lipidomics data clarifying the prostanoids present in the mouse retina and ON, and mined single-cell transcriptomic atlases of the human and mouse posterior eye to map prostanoid pathway expression across cell types. We identified species-, tissue-, and region-specific differences in prostanoid synthase and receptor expression. The PGF2α receptor (FP) was detected in mouse but not human retinal ganglion cells (RGCs). TXA2 synthase was present in ON but not retinal glia. DP2 and EP1 were enriched in microglia and astrocytes of the retrolaminar ON, but not the ON head. Analysis of mouse RGC degeneration datasets revealed dynamic regulation of prostanoid pathways in glia and RGCs. During early degeneration, macroglia upregulated PGD2 synthase (L-PGDS), while microglia upregulated the PGE2 receptor EP4. Glia downregulated intrinsic COX-1 pathways, yet we did not observe induction of COX-2. Topical NSAID treatment exacerbates RGC damage following mouse ocular hypertension, underscoring the need to clarify COX-1/2 roles in the eye. In conclusion, intrinsic prostanoid networks support retinal and ON homeostasis and are dynamically regulated in disease, representing cell-specific, receptor, and disease stage therapeutic targets, including potential RGC protection.